The estimated Net Worth of David S. Wood is at least $768 Thousand dollars as of 30 December 2022. Mr Wood owns over 8,302 units of Essa Pharma Inc stock worth over $235,402 and over the last 4 years he sold EPIX stock worth over $0. In addition, he makes $532,348 as Chief Financial Officer at Essa Pharma Inc.
Mr has made over 1 trades of the Essa Pharma Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 8,302 units of EPIX stock worth $21,585 on 30 December 2022.
The largest trade he's ever made was buying 8,302 units of Essa Pharma Inc stock on 30 December 2022 worth over $21,585. On average, Mr trades about 1,660 units every 0 days since 2020. As of 30 December 2022 he still owns at least 33,343 units of Essa Pharma Inc stock.
You can see the complete history of Mr Wood stock trades at the bottom of the page.
David S. Wood C.M.A., CPA, M.B.A., MBA, CPA, CMA is the Chief Financial Officer at Essa Pharma Inc.
As the Chief Financial Officer of Essa Pharma Inc, the total compensation of Mr CMA at Essa Pharma Inc is $532,348. There are 3 executives at Essa Pharma Inc getting paid more, with Dr. David Ross Parkinson M.D. having the highest compensation of $829,556.
Mr CMA is 64, he's been the Chief Financial Officer of Essa Pharma Inc since . There are 1 older and 1 younger executives at Essa Pharma Inc. The oldest executive at Essa Pharma Inc is Dr. David Ross Parkinson M.D., 71, who is the Pres, CEO & Director.
David's mailing address filed with the SEC is C/O ESSA PHARMA INC., 999 WEST BROADWAY, SUITE 720, VANCOUVER, A1, V5Z 1K5.
Over the last 4 years, insiders at Essa Pharma Inc have traded over $924,311 worth of Essa Pharma Inc stock and bought 3,342,445 units worth $15,321,880 . The most active insiders traders include Growth N Vbb Biotech Ag Bio..., Franklin M Berger, and Marella Thorell. On average, Essa Pharma Inc executives and independent directors trade stock every 57 days with the average trade being worth of $1,108,300. The most recent stock trade was executed by Peter Virsik on 9 September 2024, trading 694 units of EPIX stock currently worth $4,164.
as a clinical-stage pharmaceutical company founded on cutting-edge research, essa is focused on developing novel therapeutics for cancer patients. essa embraces innovation not only in our products but also in our approach. we're firmly rooted in creative and open thinking, giving us an energy and approach that makes us a different kind of pharmaceutical company.
Essa Pharma Inc executives and other stock owners filed with the SEC include: